Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00550290 |
Recruitment Status :
Completed
First Posted : October 29, 2007
Results First Posted : September 18, 2018
Last Update Posted : October 17, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Wound Infection | Drug: Cefazolin PostOperatively Drug: Cefazolin Preoperatively | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Prevention |
Official Title: | Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy |
Study Start Date : | October 2007 |
Actual Primary Completion Date : | April 2009 |
Actual Study Completion Date : | April 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Cefazolin Preoperatively
Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
|
Drug: Cefazolin Preoperatively
Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
Other Names:
|
Experimental: Cefazolin Postoperatively
Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
|
Drug: Cefazolin PostOperatively
Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
Other Names:
|
- Wound Complications [ Time Frame: Two-week post-operative ]Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All female patients 18 years of age or older undergoing surgery for vulvar carcinoma (this includes female patients undergoing any form of vulvectomy - radical, vulvectomy without groin node dissection, and partial vulvectomy)
- Disease State will not affect inclusion in the study. Women with previous surgery for vulvar carcinoma will be included as will those undergoing initial operation.
- Number of subjects: 160
Exclusion Criteria:
- Women simultaneously undergoing treatment for other forms of cancer
- Women under the age of 18
- Pregnant patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00550290
United States, Ohio | |
Aultman Health Foundation | |
Canton, Ohio, United States, 44710 |
Study Chair: | Michael P Hopkins, MD | Aultman Health Foundation | |
Principal Investigator: | William T. Schnettler, MD | Aultman Health Foundation |
Responsible Party: | Aultman Health Foundation |
ClinicalTrials.gov Identifier: | NCT00550290 |
Other Study ID Numbers: |
2007.07.26.E2 |
First Posted: | October 29, 2007 Key Record Dates |
Results First Posted: | September 18, 2018 |
Last Update Posted: | October 17, 2018 |
Last Verified: | September 2018 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
vulvectomy wound infection wound complication prophylactic antibiotic Post-operative wound complications following vulvectomy |
Wound Infection Wounds and Injuries Infections |
Cefazolin Anti-Bacterial Agents Anti-Infective Agents |